Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24364578 | 0.77 | POLB (0.49) | SCN4APOLBPTPN11KDM1APDPK1 | |
| SCHEMBL29081748 | 0.75 | CYP19A1 (0.35) | CYP19A1 | |
| SCHEMBL29325287 | 0.75 | PRCP (0.41) | POLBSMN1; SMN2CYP1A2CYP2D6CYP19A1 | |
| SCHEMBL25323065 | 0.75 | PRCP (0.41) | POLBSMN1; SMN2CYP1A2CYP2D6CYP19A1 | |
| SCHEMBL29981292 | 0.74 | AKT1 (0.41) | BRAF | |
| SCHEMBL29324103 | 0.74 | AKT1 (0.41) | BRAF | |
| SCHEMBL24233794 | 0.73 | MAPT (0.39) | KDM1ASMN1; SMN2ALDH1A1MAPTCYP1A2 | |
| SCHEMBL25321512 | 0.73 | MAPT (0.39) | KDM1ASMN1; SMN2ALDH1A1MAPTCYP1A2 | |
| SCHEMBL14963942 | 0.73 | MAPT (0.39) | KDM1ASMN1; SMN2ALDH1A1MAPTCYP1A2 | |
| SCHEMBL18923992 | 0.73 | POLB (0.55) | SCN4APOLBPTPN11KDM1APDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-11999727-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11492350-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
| WO-2022026892-A1 | PIPERIDIN-1- YL-N-PYRYDI NE-3-YL-2-OXOACET AM IDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MT A-ACCUMULATING CANCERS | TANGO THERAPEUTICS, INC. (US) | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999727-B2 | Compounds and methods of use | F12, C1R, ABCG2 | SCN4A 1624/4885POLB 3098/4885PTPN11 1533/4885 |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | SCN4A 1624/4885POLB 3098/4885PTPN11 1533/4885 |
| US-11492350-B2 | Compounds and methods of use | F12, C1R, ABCG2 | SCN4A 1624/4885POLB 3098/4885PTPN11 1533/4885 |
| US-20230113778-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | SCN4A 1624/4885POLB 3098/4885PTPN11 1533/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | SCN4A 1624/4885POLB 3098/4885PTPN11 1533/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | SCN4A 1624/4885POLB 3098/4885PTPN11 1533/4885 |
| US-20220127256-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | SCN4A 1624/4885POLB 3098/4885PTPN11 1533/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | SCN4A 1624/4885POLB 3098/4885PTPN11 1533/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | SCN4A 900/4885POLB 3899/4885PTPN11 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.